Cited by 122Health Systems, Economic Evaluations, Quality of LifeSchizophrenia research and treatmentEconomic and Environmental Valuation

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation

Open access

Briggs, Andrew, Wild, Diane, Lees, Michael, Reaney, Matthew, Dursun, Serdar, Parry, David, Mukherjee, Jayanti·2008·Health and Quality of Life Outcomes

DOI 10.1186/1477-7525-6-105PMC PMC2613374

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVE: To examine the impact of schizophrenia, its treatment and treatment-related adverse events related to antipsychotics, on quality of life from the perspective of schizophrenia patients and laypersons. METHODS: Health state descriptions for stable schizophrenia, extra pyramidal symptoms (EPS), hyperprolactinemia, diabetes, weight gain and relapse were developed based on a review of the literature and expert opinion. The quality of life impact of each health state was elicited using a time trade-off instrument administered by interview to 49 stable schizophrenia patients and 75 laypersons. Regression techniques were employed to examine the importance of subject characteristics on health-related utility scores. RESULTS: Patients and laypersons completed the interview in similar times. Stable schizophrenia had the highest mean utility (0.87 and 0.92 for laypersons and patients respectively), while relapse (0.48 and 0.60) had the lowest mean utility. Of the treatment-related adverse events, EPS had the lowest mean utility (0.57 and 0.72, respectively). Age, gender and PANSS score did not influence the utility results independently of health state. On average, patient utilities are 0.077 points higher than utilities derived from laypersons, although the ranking was similar between the two groups. CONCLUSION: Events associated with schizophrenia and treatment of schizophrenia can bring about a significant detriment in patient quality of life, with relapse having the largest negative impact. Results indicate that patients with stable schizophrenia are less willing to trade years of life to avoid schizophrenia-related symptoms compared to laypersons. Both sets of respondents showed equal ability to complete the questionnaire.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/1477-7525-6-105

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,703
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Untitled work
(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544
Projection Bias in Predicting Future Utility
Loewenstein, G. F., O’Donoghue, T., & Rabin, M. (2003) · The Quarterly Journal of Economics · doi:10.1162/003355303322552784 · Cited by 1,079
Scientific and Consumer Models of Recovery in Schizophrenia: Concordance, Contrasts, and Implications
Bellack, A. S. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj044 · Cited by 599
Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public
Ubel, P. A., Loewenstein, G. F., & Jepson, C. (2003) · Quality of Life Research · doi:10.1023/a:1025119931010 · Cited by 437
Visual Analog Scales: Do They Have a Role in the Measurement of Preferences for Health States?
Torrance, G. W., Feeny, D. H., & Furlong, W. J. (2001) · Medical Decision Making · doi:10.1177/0272989x0102100408 · Cited by 431
Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study
Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L., Kreyenbuhl, J., Revicki, D., & Buchanan, R. (2002) · BMJ · doi:10.1136/bmj.325.7358.243 · Cited by 421

Show all 21 references

Research works printed but not linked: 8

Brazier J, Akehurst R, Brennan A, Dolan P, Claxton K, McCabe C, O'Hagan A, Sculpher MJ: Tsuchyia A. Should patients have a greater role in valuing health states: whose well-being is it anyway? In Sheffield Health Economics Group Discussion Paper Series (Ref: 04/3). University of Sheffield; 2004.
National Institute for Clinical Excellence (NICE): Guide to the methods of technology assessment. London: NICE; 2004.
Willis GB: Cognitive Interviewing: A "How To" Guide. From the short course "Reducing Survey Error through Research on the Cognitive and Decision Processes in Surveys," presented at the Meeting of the American Statistical Association. 1999.
Cummins C, Stevens A, Kisely S: The use of olanzapine as a first and second choice treatment in schizophrenia, West Midlands Development and Evaluation Committee Report, Wessex Institute for Health Research and Development. 1998.
Glennie JL: Pharmacoeconomic evaluations of clozapine in treatment resistant schizophrenia and risperidone in chronic schizophrenia. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997.
Lee TT, Ziegler JK, Sommi R, Sugar C, Mahmoud R, Lenert LA: Comparison of preferences for health outcomes in schizophrenia among stakeholder groups. Journal of Psychiatric Research 2000, 34: 201–210. 10.1016/S0022-3956(00)00009-1 · DOI
Sevy S, Nathanson K, Schlecter C, Fulop G: Contingency Valuation and Preferences of Health States Associated With Side Effects of Antipsychotic Medications in Schizophrenia. Schizophrenia Bulletin 2001, 27(4):643–651. · DOI
Cardinal Broadcast: Two cases of schizophrenia. An illustrated lecture. DVD 2004. [http://www.mental-health.tv]

Sorted by citations

The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia
Correll, C. U., Davis, R. E., Weingart, M., Saillard, J., O’Gorman, C., Kane, J. M., Lieberman, J. A., Tamminga, C. A., Mates, S. L., & Vanover, K. E. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.4379 · Cited by 289
Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders
Saarni, S. I., Viertiö, S., Perälä, J., Koskinen, S., Lönnqvist, J., & Suvisaari, J. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.076489 · Cited by 251
A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach
Veronese, M., Santangelo, B., Jauhar, S., D’Ambrosio, E., Demjaha, A., Salimbeni, H., Jin, H., McCrone, P., Turkheimer, F., & Howes, O. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00866-7 · Cited by 58
What matters to patients? A systematic review of preferences for medication-associated outcomes in mental disorders
Eiring, Ø., Landmark, B. F., Aas, E., Salkeld, G., Nylenna, M., & Nytrøen, K. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007848 · Cited by 57
Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
Druais, S., Doutriaux, A., Cognet, M., Godet, A., Lançon, C., Lévy, P., Samalin, L., & Guillon, P. (2016) · PharmacoEconomics · doi:10.1007/s40273-015-0348-x · Cited by 55
Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction)
Moncrieff, J., Lewis, G., Freemantle, N., Johnson, S., Barnes, T. R. E., Morant, N. J., Pinfold, V., Hunter, R. M., Kent, L., Smith, R., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030912 · Cited by 53
Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients
Fallon, P., Dursun, S., & Deakin, B. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311431105 · Cited by 47
Self-citation
Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death
Hatswell, A. J., Pennington, B., Pericleous, L., Rowen, D., Lebmeier, M., & Lee, D. (2014) · Health and Quality of Life Outcomes · doi:10.1186/s12955-014-0140-1 · Cited by 48
A systematic review of health economic models and utility estimation methods in schizophrenia
Németh, B., Fasseeh, A. N., Molnár, A., Bitter, I., Horváth, M., Kóczián, K., Götze, Á., & Nagy, B. (2018) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2018.1430571 · Cited by 48
QLiS – development of a schizophrenia-specific quality-of-life scale
Franz, M., Fritz, M., Gallhofer, B., & Meyer, T. (2012) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-10-61 · Cited by 44
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Ruíz, A., Pérez-Costillas, L., Montesinos, A., Alcalde, J., Oyagüez, I., & Casado, M. A. (2012) · Health Economics Review · doi:10.1186/2191-1991-2-8 · Cited by 44
Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study
Osborne, R. H., Dalton, A., Hertel, J., Schrover, R., & Smith, D. (2012) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-10-35 · Cited by 39
Challenges to time trade-off utility assessment methods: when should you consider alternative approaches?
Boye, K. S., Matza, L. S., Feeny, D. H., Johnston, J. A., Bowman, L., & Jordan, J. B. (2014) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2014.912562 · Cited by 42
Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials
Kane, J. M., Durgam, S., Satlin, A., Vanover, K. E., Chen, R., Davis, R. E., & Mates, S. L. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000371 · Cited by 38
Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden
Mehnert, A., Nicholl, D., Pudas, H., Martin, M., & McGuire, A. J. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.681531 · Cited by 34
Live Like Nobody Is Watching
Ho, A. (2023) · doi:10.1093/med/9780197556269.001.0001 · Cited by 35
Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia
Correll, C. U., Vanover, K. E., Davis, R. E., Chen, R., Satlin, A., & Mates, S. L. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.12.006 · Cited by 33
Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
Zeidler, J., Mahlich, J., Greiner, W., & Heres, S. (2013) · Applied Health Economics and Health Policy · doi:10.1007/s40258-013-0050-0 · Cited by 32
Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
Park, T., & Kuntz, K. M. (2014) · Value in Health · doi:10.1016/j.jval.2014.02.008 · Cited by 31
Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden
Einarson, T. R., Vicente, C., Zilbershtein, R., Piwko, C., Bø, C. N., Pudas, H., Jensen, R., & Hemels, M. E. H. (2013) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2013.852243 · Cited by 28
Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
Einarson, T. R., Geitona, M., Chaidemenos, A., Karpouza, V., Mougiakos, T., Paterakis, P., Ploumpidis, D., Potamitis-Komis, D., Zilbershtein, R., Vicente, C., et al. (2012) · Annals of General Psychiatry · doi:10.1186/1744-859x-11-18 · Cited by 27
Predictors of Health-Related Quality-of-Life Utilities Among Persons With Posttraumatic Stress Disorder
Doctor, J. N., Zoellner, L. A., & Feeny, N. C. (2011) · Psychiatric Services · doi:10.1176/ps.62.3.pss6203_0272 · Cited by 26
Effectiveness and cost-effectiveness of a cardiovascular risk prediction algorithm for people with severe mental illness (PRIMROSE)
Zomer, E., Osborn, D., Nazareth, I., Blackburn, R. M., Burton, A., Hardoon, S. L., Holt, R. I. G., King, M., Marston, L., Stephen Morris, A., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-018181 · Cited by 22
Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland
Einarson, T. R., Pudas, H., Goswami, P., Impe, K. V., & Bereza, B. G. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1100115 · Cited by 24
Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria
Murray, R. M., Correll, C. U., Reynolds, G. P., & Taylor, D. M. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317693200 · Cited by 23
Human health benefits and burdens of a pharmaceutical treatment: Discussion of a conceptual integrated approach
Debaveye, S., Soete, W. D., Meester, S. D., Vandijck, D. M., Heirman, B., Kavanagh, S., & Dewulf, J. P. (2015) · Environmental Research · doi:10.1016/j.envres.2015.10.027 · Cited by 22
Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal
Einarson, T. R., Maia-Lopes, S., Goswami, P., Bereza, B. G., & Impe, K. V. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1184156 · Cited by 22
Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia
Buoli, M., Kahn, R. S., Serati, M., Altamura, A. C., & Cahn, W. (2016) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2542 · Cited by 22
Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections
Debaveye, S., Smedt, D. D., Heirman, B., Kavanagh, S., & Dewulf, J. P. (2019) · BMC Health Services Research · doi:10.1186/s12913-019-4247-2 · Cited by 23
Elicitation of Informed General Population Health State Utility Values: A Review of the Literature
McTaggart-Cowan, H. M. (2011) · Value in Health · doi:10.1016/j.jval.2011.05.046 · Cited by 22
Short term effects of brief need based psychoeducation on knowledge, self-stigma, and burden among siblings of persons with schizophrenia: A prospective controlled trial
Amaresha, A. C., Kalmady, S. V., Joseph, B., Agarwal, S. M., Narayanaswamy, J. C., Venkatasubramanian, G., Muralidhar, D., & Subbakrishna, D. K. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.11.030 · Cited by 21
Cost-Effectiveness of School-Based Prevention of Cannabis Use
Deogan, C., Zarabi, N., Stenström, N., Högberg, P., Skärstrand, E., Manrique-Garcia, E., Neovius, K., & Månsdotter, A. (2015) · Applied Health Economics and Health Policy · doi:10.1007/s40258-015-0175-4 · Cited by 20
A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States
Mavranezouli, I. (2010) · PharmacoEconomics · doi:10.2165/11537300-000000000-00000 · Cited by 20
Clinical outcomes from the texting for relapse prevention (T4RP) in schizophrenia and schizoaffective disorder study
Cullen, B., Rodriguez, K. M., Eaton, W. W., Mojtabai, R., Mach, T. V., & Ybarra, M. L. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113346 · Cited by 19
Health State Utility Values in Schizophrenia: A Systematic Review and Meta-Analysis
Aceituno, D., Pennington, M., Iruretagoyena, B., Prina, M. A., & McCrone, P. (2020) · Value in Health · doi:10.1016/j.jval.2020.05.014 · Cited by 17
Cognitive Behavioural Therapy for Psychosis: A Health Technology Assessment.
(2018) · Europe PMC (PubMed Central) · Cited by 17
Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway
Einarson, T. R., Vicente, C., Zilbershtein, R., Piwko, C., Bø, C. N., Pudas, H., & Hemels, M. E. H. (2012) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2012.00670.x · Cited by 17
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Rajagopalan, K., Trueman, D., Crowe, L., Squirrell, D., & Loebel, A. D. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0405-0 · Cited by 17
Economic evaluation of paliperidone palmitate once monthly for treating chronic schizophrenia patients in the United Arab Emirates
Nuhoho, S., Saad, A., Saumell, G., Ribes, D., & Khoury, A. C. E. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1417246 · Cited by 16
Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland
Einarson, T. R., Pudas, H., Zilbershtein, R., Jensen, R., Vicente, C., Piwko, C., & Hemels, M. E. H. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.823869 · Cited by 16
Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes
Sawyer, L., Azorin, J., Chang, S., Rinciog, C., Guiraud-Diawara, A., Marre, C., & Hansen, K. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.914030 · Cited by 15
Stratified Medicine in Schizophrenia - How Accurate Would a Test of Drug Response Need to Be to Achieve Cost-Effective Improvements in Quality of Life?
Jin, H., McCrone, P., & MacCabe, J. H. (2018) · The European Journal of Health Economics · doi:10.1007/s10198-019-01108-4 · Cited by 15
Perspectives about Illness, Attitudes, and Caregiving Experiences among Siblings of Persons with Schizophrenia: A Qualitative Analysis
Amaresha, A. C., Venkatasubramanian, G., & Muralidhar, D. (2019) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_318_19 · Cited by 15
Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
Zhou, J., Millier, A., François, C., Aballéa, S., & Toumi, M. (2019) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2019.1648973 · Cited by 15
The effect of the medicine administration route on health-related quality of life: Results from a time trade-off survey in patients with bipolar disorder or schizophrenia in 2 Nordic countries
Jørgensen, T. R., Emborg, C., Dahlen, K., Bøgelund, M., & Carlborg, A. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0930-6 · Cited by 14
Utility decrements associated with side effects in schizophrenia
Millier, A., Amri, I., Boyer, L., Auquier, P., & Toumi, M. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.964405 · Cited by 14
Updating and Confirming an Industry-Sponsored Pharmacoeconomic Model: Comparing Two Antipsychotics in the Treatment of Schizophrenia
Graham, C. N., Mauskopf, J., Lawson, A. H., Ascher‐Svanum, H., & Bruhn, D. F. (2011) · Value in Health · doi:10.1016/j.jval.2011.08.1741 · Cited by 14
Primary care management of cardiovascular risk for people with severe mental illnesses: the Primrose research programme including cluster RCT
Osborn, D., Burton, A., Walters, K. R., Atkins, L., Barnes, T. R. E., Blackburn, R. M., Craig, T., Gilbert, H. M., Gray, B. V., Hardoon, S. L., et al. (2019) · Programme Grants for Applied Research · doi:10.3310/pgfar07020 · Cited by 13
Assessing the needs of siblings of persons with schizophrenia: A qualitative study from India
Amaresha, A. C., Joseph, B., Agarwal, S. M., Narayanaswamy, J. C., Venkatasubramanian, G., Muralidhar, D., & Subbakrishna, D. K. (2015) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2015.07.011 · Cited by 14
Cost-Effectiveness of Asenapine in the Treatment of Patients with Bipolar I Disorder with Mixed Episodes in an Italian Context
Caresano, C., Sciascio, G. D., Fagiolini, A. M., Maina, G., Perugi, G., Ripellino, C., & Vampini, C. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0139-3 · Cited by 13
Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic
Einarson, T. R., Zilbershtein, R., Skoupá, J., Veselá, Š., Garg, M., & Hemels, M. E. H. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.820193 · Cited by 13
Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia
von Scheele, B., Mauskopf, J., Brodtkorb, T., Ainsworth, C., Berardo, C. G., & Patel, A. K. (2014) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2014.891443 · Cited by 13
Impact of drug-induced Parkinsonism and tardive dyskinesia on health-related quality of life in schizophrenia
Rekhi, G., Tay, J., & Lee, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211055812 · Cited by 12
Estimation of a Multiattribute Utility Function for the Spanish Version of the TooL Questionnaire
Montejo, A. L., Correas-Lauffer, J., Mauriño, J., Villa, G., Rebollo, P., Díez, T., & Cordero, L. (2011) · Value in Health · doi:10.1016/j.jval.2010.11.016 · Cited by 12
Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study
King, D., Knapp, M. R. J., Thomas, P., Razzouk, D., Loze, J.-Y., Kan, H., & van Baardewijk, M. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.542745 · Cited by 12
A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder
Mavranezouli, I., & Lokkerbol, J. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0473-1 · Cited by 13
Estimating utility value for female genital mutilation
Alinia, C., Piroozi, B., Jahanbin, F., Safari, H., Bolbanabad, A. M., Karyani, A. K., Moradi, G., Farhadifar, F., & Ebrahimi, M. (2020) · BMC Public Health · doi:10.1186/s12889-020-08947-4 · Cited by 11
Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia
Awad, G. A., Hassan, M., Loebel, A. D., Hsu, J., Pikalov, A., & Rajagopalan, K. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-53 · Cited by 11
Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia
Jukić, V., Jakovljević, M., Filipčić, I., Herceg, M., Silić, A., Tomljanović, T., Zilbershtein, R., Jensen, R., Hemels, M. E. H., & Einarson, T. R. (2013) · Value in Health Regional Issues · doi:10.1016/j.vhri.2013.06.008 · Cited by 12
A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia
Wang, L., Shi, F., Guan, X., Xu, H., Liu, J., & Li, H. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.689123 · Cited by 10
Developing Texting for Relapse Prevention: A Scalable mHealth Program for People With Schizophrenia and Schizoaffective Disorder
Ybarra, M. L., Rodriguez, K. M., Madison, H., Mojtabai, R., & Cullen, B. (2019) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001037 · Cited by 9
Aripiprazole for the Treatment and Prevention of Acute Manic and Mixed Episodes in Bipolar I Disorder in Children and Adolescents: A NICE Single Technology Appraisal
Uttley, L., Kearns, B., Ren, S., & Stevenson, M. (2013) · PharmacoEconomics · doi:10.1007/s40273-013-0091-0 · Cited by 9
Validation of a specific measure to assess health-related quality of life in patients with schizophrenia and bipolar disorder: the 'Tolerability and quality of life' (TOOL) questionnaire
Montejo, A. L., Correas-Lauffer, J., Cuervo, J., Rebollo, P., Cordero, L., Díez, T., & Mauriño, J. (2011) · Annals of General Psychiatry · doi:10.1186/1744-859x-10-6 · Cited by 9
The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study
Duarte, C., Fakra, É., van Gils, C., & Guillon, P. (2019) · L Encéphale · doi:10.1016/j.encep.2019.03.001 · Cited by 8
Economic evaluation of the use of a pharmacogenetic diagnostic test in schizophrenia
Rejón-Parrilla, J. C., Nuijten, M. J. C., Redekop, K., & Gaultney, J. G. (2014) · Health Policy and Technology · doi:10.1016/j.hlpt.2014.08.004 · Cited by 8
What utility scores do mental health service users, healthcare professionals and members of the general public attribute to different health states? A co-produced mixed methods online survey
Flood, C., Barlow, S. H., Simpson, A., Burls, A., Price, A. I., Cartwright, M., & Brini, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205223 · Cited by 8
Haloperidol Versus Second-Generation Antipsychotics in the Long-Term Treatment of Schizophrenia
Altamura, A. C., Buoli, M., & Mauri, M. C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822c989a · Cited by 7
Physical activity and severe mental illness
Fibbins, H., Lederman, O., & Rosenbaum, S. (2021) · Society for Transparency, Openness, and Replication in Kinesiology eBooks · doi:10.51224/b1017 · Cited by 7
Acceptability of Texting 4 Relapse Prevention, Text Messaging-Based Relapse Prevention Program for People With Schizophrenia and Schizoaffective Disorder
Ybarra, M. L., Rodriguez, K. M., Fehmie, D. A., Mojtabai, R., & Cullen, B. (2021) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001421 · Cited by 7
Quality of life and functioning in first‐episode psychosis C hinese patients with different antipsychotic medications
Lee, E. H. M., Hui, C. L. M., Lin, J., Ching, E. Y. N., Chang, W. C., Chan, S. K. W., & Chen, E. Y. H. (2015) · Early Intervention in Psychiatry · doi:10.1111/eip.12246 · Cited by 8
Quality of Life in Psychosis: Prevalence and Associated Factors in a Nigerian Clinical Population
Lasebikan, V. O., & Owoaje, E. (2015) · Community Mental Health Journal · doi:10.1007/s10597-015-9842-z · Cited by 9
Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model
Furiak, N. M., Gahn, J. C., Klein, R. W., Camper, S. B., & Summers, K. H. (2012) · Annals of General Psychiatry · doi:10.1186/1744-859x-11-29 · Cited by 7
Quantifying the handprint—Footprint balance into a single score: The example of pharmaceuticals
Debaveye, S., Smedt, D. D., Heirman, B., Kavanagh, S., & Dewulf, J. P. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229235 · Cited by 7
Evaluation of health promotion programmes in severe mental illness: theory and practice
van Hasselt, F. M., Krabbe, P. F. M., Postma, M. J., & LOONEN, A. J. M. (2014) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1456 · Cited by 8
Cortical morphometric correlational networks associated with cognitive deficits in first episode schizophrenia
Wang, C., Oughourlian, T. C., Tishler, T. A., Anwar, F., Raymond, C., Pham, A. D., Perschon, A., Villablanca, J. P., Ventura, J., Subotnik, K. L., et al. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.04.001 · Cited by 7
Valuation of depression co‐occurring with a somatic condition: feasibility of the time trade‐off task
Papageorgiou, K., Vermeulen, K. M., Leijten, F., Buskens, E., Ranchor, A. V., & Schroevers, M. J. (2014) · Health Expectations · doi:10.1111/hex.12303 · Cited by 6
Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain
Quintero, J., Oyagüez, I., González, B., Cuervo-Arango, I., García, I., & Casado, M. Á. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0393-z · Cited by 5
Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China
Yi, Z., Men, P., Qu, S., Li, C., Yu, X., & Zhai, S. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1752670 · Cited by 4
Acknowledging Patient Heterogeneity in Economic Evaluations in Schizophrenia: A Systematic Review
Shields, G., Camacho, E. M., Farragher, T. M., Clarkson, P., Verma, A., & Davies, L. M. (2021) · Value in Health · doi:10.1016/j.jval.2021.07.001 · Cited by 4
Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
Liu, J., Cao, L., & Wu, J. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.987408 · Cited by 4
Cost-Effectiveness of Injectable Atypical Long-Acting Antipsychotics for Chronic Schizophrenia in Poland
Hemels, M. E. H., Einarson, T. R., Zilbershtein, R., Schubert, A., Skrzekowska-Baran, I., & Impe, K. V. (2013) · Value in Health · doi:10.1016/j.jval.2013.08.1406 · Cited by 4
Health utility estimation in children and adolescents: a review of health technology assessments
Bégo-Le-Bagousse, G., Jia, X., Wolowacz, S. E., Eckert, L., Tavi, J., & Hudson, R. D. A. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1762553 · Cited by 4
Adaptation and validation of the “tolerability and quality of life” (TOOL) questionnaire in Chinese bipolar patients
Xiao, L., Gao, Y., Zhang, L., Chen, P., Sun, X., & Tang, S. (2016) · Quality of Life Research · doi:10.1007/s11136-016-1319-1 · Cited by 3
Dopamine docking studies of biologically active metabolites from Curcuma longa L.
Bernardi, D. M., Marchi, J. P., Araújo, C. D. S. A., do Nascimento, V. R., Lima, D. D. S., Wietzikoski, S., Ferro, M. M., Miyoshi, E., Lívero, F. A. D. R., Seixas, F. A. V., et al. (2021) · Research Society and Development · doi:10.33448/rsd-v10i7.16992 · Cited by 4
Improving the physical health of people with severe mental illness: The need for tailor made care and uniform evaluation of interventions
van Hasselt, F. M. (2013) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 3
Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
Luo, R., Lu, H., & Li, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1238028 · Cited by 2
Cost/effectiveness of aripiprazole vs. olanzapine in the long-term treatment of schizophrenia
Dutina, A., Stašević-Karličić, I., Pandrc, N., Prokić, A., & Јаnkovic, S. (2019) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh181012065d · Cited by 2
Economic considerations of cognition and functional outcomes in patients with schizophrenia: A systematic literature review
Furiak, N. M., Duhig, A. M., Myers, J. A., Pitts, A., Hass, S., & Klein, R. W. (2014) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2013.11.001 · Cited by 2
Translating genomic research into care for people with schizophrenia in China
Chan, R. C. K., Austin, J., Pearson, V. J., Gong, Q., & Honer, W. G. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.05.008 · Cited by 2
Cost-effectiveness analysis of paliperidone palmitate versus long-acting risperidone as maintenance treatment in schizophrenia patients in Italy
Ravasio, R., Nicolò, G., & Vaggi, M. (2014) · Global & Regional Health Technology Assessment · doi:10.5301/grhta.5000186 · Cited by 2
Paranoid Thinking and Wellbeing. The Role of Doubt in Pharmacological and Metacognitive Therapies
Aguerri, L. A., Beato‐Fernández, L., Stavraki, M., Rodríguez‐Cano, T., Bajo, M., & Díaz, D. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.02099 · Cited by 3
Outcomes Measurement for Economic Evaluation
Razzouk, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-55266-8_3 · Cited by 2
A Digital Pill to Swallow
Ho, A. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197556269.003.0005 · Cited by 1
Cost-effectiveness of injectable atypical long-acting antipsychotics for chronic schizophrenia in Poland
Hemels, M. E. H., Zilbershtein, R., Schubert, A., Skrzekowska-Baran, I., & Impe, K. V. (2013) · Journal of Health Policy & Outcomes Research · doi:10.7365/jhpor.2013.4.6 · Cited by 1
Cost-Utility and Budget Impact Analyses Comparing Lurasidone with Aripiprazole in Adults with Schizophrenia in Scotland
Rajagopalan, K., Trueman, D., Crowe, L., Patel, P., & Loebel, A. D. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.968 · Cited by 1
Introduction
Ho, A. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197556269.003.0001 · Cited by 1
A cost-utility analysis of Amisulpride and Paliperidone in the treatment of Schizophrenia
Abdall-Razak, A., Macaulay, A., Tiefenbach, J., Borges, K., Mathema, S., & Zuberi, S. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02343 · Cited by 1
Limitations of access to antipsychotics in Canada: loss of the old and unavailability of the new options
Zhand, N., Desai, N., Park, A., & Dick, M. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01426-3 · Cited by 1
The derivation of a preference-based measure for people with common mental health problems from the Clinical Outcomes in Routine Evaluation Outcome Measure (CORE-OM)
Mavranezouli, I. (2014) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)

Authors: Briggs, A., Wild, D., Lees, M., Reaney, M., Dursun, S., Parry, D., & Mukherjee, J.
Affiliations: University of Manchester (GB)
Bristol-Myers Squibb (United Kingdom) (GB)
Corresponding author: Wild, Diane
ORCID: Briggs, Andrew
Reaney, Matthew
Dursun, Serdar
Mukherjee, Jayanti
Venue: Health and Quality of Life Outcomes
Publisher: Springer Science and Business Media LLC
Published: 2008-11-28
Volume: 6
Issue: 1
Pages: 105-105
ISSN: 1477-7525 (ISSN-L)
DOI: 10.1186/1477-7525-6-105
PMC: PMC2613374
OpenAlex: W2168395707
Cited by: 122
References: 21
Citations by year: 2026: 4 · 2025: 1 · 2023: 14 · 2022: 3 · 2021: 8 · 2020: 9 · 2019: 11 · 2018: 5 · 2017: 4 · 2016: 8 · 2015: 8 · 2014: 16 · 2013: 9 · 2012: 7
FWCI: 11.51
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
Locations: Health and Quality of Life Outcomes (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Funders: Bristol-Myers Squibb
University of Manchester
Deakin University
University of Toronto
Topics: Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Environmental Valuation
Keywords: schizophrenia, quality of life, antipsychotic adverse effects, hyperprolactinemia, antipsychotic-induced diabetes, weight gain, relapse, health utility, time trade-off, health state descriptions
MeSH terms: Adolescent, Adult, Aged, England, Female, Humans, Interviews as Topic, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Schizophrenia, Antipsychotic Agents, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks